GlobeNewswire Inc | Nov 10, 2020 08:00AM EST

November 10, 2020

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, announced today it will host a conference call and webcast to provide a business update onTuesday, November 17, 2020at4:30 p.m. EST. Live and archived versions of the event can be accessed via the Companyswebsite.

Members of theCue Biopharmaexecutive management team will provide a clinical update including details pertaining to patients from cohorts 4, 5 and 6 in the Companys ongoing Phase 1 monotherapy dose escalation clinical trial of CUE-101for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Management will also provide an update on the Companys technology platforms and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.

Tuesday, November 17 at4:30 p.m. EST

Investors: 877-407-9208International: 201-493-6784Conference ID: 13712195Webcast: http://public.viavid.com/index.php?id=142111

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate DevelopmentCue Biopharma, Inc.gzavoico@cuebio.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com